Coherus Oncology stock falls 5.38 percent in trading
Published on 10/08/2026 at 11:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Coherus Oncology (ISIN US19249H1032) was trading at EUR 0.88 at Lang & Schwarz on October 8, 2026 at 10:58 a.m. CEST, down 5.38 percent versus the EUR 0.93 prior close. The market move came as the company remained centered on its oncology portfolio and the commercial development of LOQTORZI.
Revenue rose in the second quarter
Coherus Oncology reported USD 14.31 million in revenue for the second quarter of 2026, up 39.53 percent from the same quarter a year earlier, according to Quiver Quant. The comparison gives the current price move a different operating backdrop, because reported revenue was expanding even as the stock traded at a low absolute level.
The company describes LOQTORZI as an approved next-generation programmed death receptor-1 inhibitor and is advancing Tagmokitug and Casdozokitug in mid-stage clinical programs, according to Coherus Oncology in its September 23, 2026 release.
Analyst targets remain higher
Zacks listed four short-term analyst targets averaging USD 7.75, with a low of USD 4.00 and a high of USD 10.00. Those dollar targets belong to Nasdaq-listed CHRS and are separate from the euro quotation used for the German investor perspective.
Coherus Oncology had a USD 156.0 million market capitalization as of October 7, 2026. The combination of a small market value, a 39.53 percent year-over-year revenue increase in the second quarter and a wide analyst target range leaves commercial execution and clinical progress as the key measurable variables.
Trading snapshot for October 8
At Lang & Schwarz, Coherus Oncology was trading at EUR 0.88 on October 8, 2026 at 10:58 a.m. CEST, down 5.38 percent from the EUR 0.93 prior close. The primary listing is Nasdaq, where the quotation currency is USD.
The further course of trading is shown by the continuously updated real-time quote of Coherus Oncology stock.
Coherus Oncology stock facts
- Company: Coherus Oncology, Inc.
- ISIN: US19249H1032
- Ticker: CHRS
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 8, 2026 at 10:58 a.m. CEST: EUR 0.88
- Change versus prior close: minus 5.38 percent
- Prior close Lang & Schwarz October 7, 2026: EUR 0.93
- Market capitalization: USD 156.0 million as of October 7, 2026
- Sector / Industry: Healthcare / Biotechnology
